Arcus Biosciences, Inc.RCUSNYSE
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
1.44%
↓ 90% below average
Average (34q)
13.74%
Historical baseline
Range
High:173.62%
Low:-43.34%
Volatility
1579.2%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 1.44% |
| Q2 2025 | 13.93% |
| Q1 2025 | 20.79% |
| Q4 2024 | -17.89% |
| Q3 2024 | 6.96% |
| Q2 2024 | 5.50% |
| Q1 2024 | 17.20% |
| Q4 2023 | 13.41% |
| Q3 2023 | -2.38% |
| Q2 2023 | 3.70% |
| Q1 2023 | 1.00% |
| Q4 2022 | 4.16% |
| Q3 2022 | 10.00% |
| Q2 2022 | 14.75% |
| Q1 2022 | 22.16% |
| Q4 2021 | -29.92% |
| Q3 2021 | 3.61% |
| Q2 2021 | 3.59% |
| Q1 2021 | 36.28% |
| Q4 2020 | -5.96% |
| Q3 2020 | 45.13% |
| Q2 2020 | 54.23% |
| Q1 2020 | 11.87% |
| Q4 2019 | 19.98% |
| Q3 2019 | -31.03% |
| Q2 2019 | 60.72% |
| Q1 2019 | 36.01% |
| Q4 2018 | -11.07% |
| Q3 2018 | -6.13% |
| Q2 2018 | 17.57% |
| Q1 2018 | -4.07% |
| Q4 2017 | -43.34% |
| Q3 2017 | 173.62% |
| Q2 2017 | 34.98% |
| Q1 2017 | 0.00% |